About the Company
BioPharmics LLC was founded in 1998 to develop algorithms and software for computational drug design. We have leading solutions in the areas of molecular docking, molecular similarity, off-target prediction, and binding affinity prediction. All methods within the Surflex platform couple physical realism in modeling protein-ligand interactions with algorithms for rapid optimization of conformation and alignment of small molecules. BioPharmics LLC has implemented efficient and unique solutions with state-of-the-art performance.
Commercial licensing of BioPharmics LLC products is done directly with us. Integration of the Surflex modules with molecular modeling packages such as Certara/SYBYL, CCG/MOE, and other platforms is expanding.